RIVER VISION DEVELOPMENT
River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.
RIVER VISION DEVELOPMENT
Industry:
Health Care Therapeutics Wellness
Founded:
2011-01-01
Address:
New York, New York, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
33.3 M USD
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Pandion Therapeutics
Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Investors List
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series A - River Vision Development
Narrow River Management
Narrow River Management investment in Series A - River Vision Development
SR One
SR One investment in Series A - River Vision Development